Media coverage about Pieris Pharmaceuticals (NASDAQ:PIRS) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Pieris Pharmaceuticals earned a news impact score of 0.03 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 46.609467977615 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the headlines that may have impacted Accern’s analysis:
- Pieris Pharmaceuticals Inc (PIRS) Expected to Post Q1 2018 Earnings of $0.36 Per Share (americanbankingnews.com)
- Eye-Catching Stock Analysis – Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) – The Investor Guide (wallstreetnews24.com)
- Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) – Hot Stock to Track – Nasdaq Journal (nasdaqjournal.com)
- Pieris Pharmaceuticals (PIRS) Now Covered by Analysts at Jefferies Group (americanbankingnews.com)
- Pieris Pharmaceuticals (PIRS) Now Covered by Evercore ISI (americanbankingnews.com)
PIRS stock traded up $0.22 on Wednesday, reaching $7.68. 207,571 shares of the company’s stock traded hands, compared to its average volume of 933,274. The company has a market cap of $388.84, a PE ratio of -18.20 and a beta of 1.50. Pieris Pharmaceuticals has a 1-year low of $2.26 and a 1-year high of $9.75.
In other news, major shareholder Orbimed Advisors Llc sold 7,897 shares of the company’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $8.98, for a total transaction of $70,915.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 4.05% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: This article was first posted by BBNS and is the sole property of of BBNS. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://baseballnewssource.com/2018/03/21/pieris-pharmaceuticals-pirs-receiving-somewhat-favorable-news-coverage-study-shows/2027889.html.
Pieris Pharmaceuticals Company Profile
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.